Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Patients with metastatic breast cancer who have responded to a first line induction chemotherapy treatment.~* Age: at least 18 years old.~* Performance status Eastern Cooperative Oncology Group (ECOG) scale 0, 1, 2.~* Normal cardiac function, confirmed by left ventricular ejection fraction (LVEF).~* Hematology: leucocytes \>= 4 x 10\^9/l; neutrophils \>= 2.0 x 10\^9/l; platelets \>= 100 x 10\^9/l; hemoglobin \<= 10 g/dl.~* Hepatic function: total bilirubin \< 1 upper limit of normal (UNL); aspartate aminotransferase (ASAT) (SGOT) and alanine aminotransferase (ALAT) (SGPT) \< 2.5 UNL; alkaline phosphatase \< 5 UNL. Patients with ASAT (SGOT) and ALAT (SGPT) \> 1.5 UNL and alkaline phosphatase \> 2.5 UNL are not eligible.~* Renal function: creatinine \< 175 mmol/l (2 mg/dl); creatinine clearance \> 45 ml/min.~Exclusion Criteria:~* Pregnant or lactating patients.~* Previous cardiac dysfunction grade II or higher as per New York Heart Association, along with congestive cardiac failure.~* Hypersensitivity to anthracyclines or Cremophor®.~* Clinically significant hepatic dysfunction.~* Current uncontrolled infection.~* Mental confusion and lack of orientation.~* Any circumstance precluding an adequate follow-up.~* Radiotherapy in the previous 4 weeks.~* Any other concurrent neoplasm, except for basal cell carcinoma or in situ carcinoma.~* Symptomatic metastasis in the brain.~* Previous radiotherapy radiating a third of haematopoietic centres.~* Males.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: PLD (Type: EXPERIMENTAL): Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
- Arm B: Observation (Type: NO_INTERVENTION): Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).